The estimated Net Worth of Pamela Esposito is at least $2.89 Milhão dollars as of 11 September 2023. Dr Esposito owns over 5,658 units of Replimune Inc stock worth over $2,734,942 and over the last 6 years he sold REPL stock worth over $158,853.
Dr has made over 17 trades of the Replimune Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he exercised 5,658 units of REPL stock worth $18,671 on 11 September 2023.
The largest trade he's ever made was exercising 87,000 units of Replimune Inc stock on 13 December 2018 worth over $152,250. On average, Dr trades about 13,362 units every 62 days since 2018. As of 11 September 2023 he still owns at least 263,736 units of Replimune Inc stock.
You can see the complete history of Dr Esposito stock trades at the bottom of the page.
Dr. Pamela Esposito Ph.D. is the Chief Bus. Officer at Replimune Inc.
Dr D is 46, he's been the Chief Bus. Officer of Replimune Inc since . There are 8 older and no younger executives at Replimune Inc. The oldest executive at Replimune Group Inc is Dr. Colin A. Love Ph.D., 63, who is the Chief Operating Officer.
Pamela's mailing address filed with the SEC is C/O KYMERA THERAPEUTICS, INC., 500 NORTH BEACON STREET, 4TH FLOOR, WATERTOWN, MA, 02472.
Over the last 6 years, insiders at Replimune Inc have traded over $72,652,546 worth of Replimune Inc stock and bought 2,360,000 units worth $33,565,200 . The most active insiders traders include Group, Llc Green Jeremy Red..., Capital Life Sciences Inves..., eJason P Rhodes. On average, Replimune Inc executives and independent directors trade stock every 21 days with the average trade being worth of $508,649. The most recent stock trade was executed by Emily Luisa Hill on 16 August 2024, trading 8,938 units of REPL stock currently worth $90,989.
replimune group, inc., a biotechnology company, develops oncolytic immune-gene therapies to treat cancer. it uses its proprietary immulytic platform to design and develop product candidates that are intended to activate the immune system against cancer. the company's lead product candidate is rp1, a selectively replicating version of herpes simplex virus 1, which is in phase i/ii clinical trials for a range of solid tumors; and that is in phase ii clinical trials for patients with cutaneous squamous cell carcinoma. it is also developing rp2, which is in phase i clinical trials for an anti-ctla-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by ctla-4; and rp3 to express immune-activating proteins that stimulate t cells. replimune group, inc. was founded in 2015 and is headquartered in woburn, massachusetts.
Replimune Inc executives and other stock owners filed with the SEC include: